Standard Operating Procedure for Market Entry Escalation and Issue Resolution
| Department | Regulatory Affairs |
| SOP No. | RA/2026/662 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 10/04/2026 |
| Effective Date | 10/04/2026 |
| Review Date | 10/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a systematic and controlled approach for escalating and resolving issues encountered during the market entry process of pharmaceutical products. The objective is to ensure timely identification, communication, evaluation, and resolution of regulatory, quality, or operational challenges to maintain compliance with applicable regulatory requirements and company standards, thereby facilitating smooth product registration and market access.
Scope
This SOP applies to all functions involved in the market entry activities within Regulatory Affairs, Quality Assurance, Quality Control, Manufacturing, and related departments. It covers the escalation and resolution processes for issues linked to product registrations, submissions, compliance deviations, documentation, and communication with regulatory authorities for any dosage form or pharmaceutical product. Exclusions include routine customer complaints and post-market surveillance issues, which are handled under separate procedures.
Responsibilities
- The Regulatory Affairs Team is responsible for identifying market entry issues and initiating the escalation process.
- Quality Assurance shall oversee review and verification of the escalated issues and approve resolution plans.
- Departmental Heads shall supervise the timely execution of corrective actions within their areas.
- Compliance and Documentation teams shall support tracking, documentation, and filing of all related records.
- The Issue Resolution Committee shall evaluate complex issues and recommend appropriate solutions.
Accountability
The Head of Regulatory Affairs holds overall accountability for implementation, adherence, periodic review, and continuous improvement of this SOP. Escalation beyond defined levels, final approvals on resolution outcomes, and ensuring effectiveness of corrective actions also rest with this role.
Procedure
The procedure for Market Entry Escalation and Issue Resolution consists of the following stages to be executed in a timely and controlled manner:
1. Identification and Documentation: All personnel engaged in market entry processes must be vigilant to detect any deviations, obstacles, or regulatory queries that can potentially impact timely product registration or launch. Upon identification, the issue shall be documented clearly with details including nature, date/time, implicated product, and source of discovery. Use the Market Entry Issue Log (See Annexure-1) for initial recording.
2. Categorization and Initial Assessment: The Regulatory Affairs coordinator or designated personnel must categorize the issue based on its criticality, impact on timelines, regulatory compliance, and potential business implications. Initial assessment involves gathering relevant facts, supporting documents, and stakeholder inputs to define the scope and severity.
3. Escalation Initiation: Issues deemed significant beyond predefined thresholds shall be escalated to the Regulatory Affairs Manager immediately. The issue report shall include completed Market Entry Issue Log and an initial impact assessment. Escalation timing must comply with internal defined timelines to avoid market delays.
4. Investigation and Root Cause Analysis: Upon escalation, a Cross-Functional Team or the Issue Resolution Committee shall review the issue in detail. The team performs root cause analysis using systematic tools (e.g., 5 Whys, Fishbone diagrams) and consults regulatory guidelines, product dossiers, or external agencies as needed to understand cause and implications fully.
5. Development of Resolution Plan: Based on investigation results, the team drafts a corrective and preventive action (CAPA) plan to resolve the issue considering regulatory compliance, quality standards, and business requirements. The plan includes timelines, responsible persons, resource allocation, and impact mitigation strategies.
6. Review and Approval of Resolution Plan: The CAPA plan undergoes review by Quality Assurance and final approval by Head of Regulatory Affairs. Any required regulatory notifications or filings are identified at this stage and scheduled accordingly.
7. Implementation of Corrective Actions: Assigned departments execute the approved action plan with documented evidence of each step. Progress is tracked rigorously using the Market Entry Issue Tracking Sheet (Annexure-2).
8. Verification and Closure: Upon completion, the Issue Resolution Committee verifies effectiveness of implemented actions by reviewing outcomes against acceptance criteria established in the plan. Confirmation that no residual risks remain is required prior to formal closure.
9. Documentation and Record Retention: All documents such as issue logs, investigation records, CAPA plans, approvals, communication records, and closure reports must be filed according to company document control policies. Records shall be maintained for the regulatory-required retention period.
10. Periodic Review and Continuous Improvement: Periodic reviews of issue trends and resolution effectiveness shall be performed at least annually by the Regulatory Affairs head to identify systemic weaknesses. Lessons learned feed into training programs, SOP updates, and process improvements.
This procedure ensures a structured approach aligned with GMP, regulatory expectations, and quality management principles for seamless market entry activities.
Abbreviations
- CAPA – Corrective and Preventive Action
- GMP – Good Manufacturing Practices
- QA – Quality Assurance
- QC – Quality Control
- SOP – Standard Operating Procedure
- RA – Regulatory Affairs
- IFA – Interim Functional Approval
Documents
Documents, forms, and logs specifically required for this SOP include:
- Market Entry Issue Log (Annexure-1)
- Market Entry Issue Tracking Sheet (Annexure-2)
- Corrective and Preventive Action Plan Template (Annexure-3)
References
- ICH Q10 – Pharmaceutical Quality System
- FDA Guidance for Industry – Quality Systems Approach to Pharmaceutical CGMP Regulations
- EMA Guidelines on Process Validation
- ISO 9001:2015 Quality Management Systems Requirements
- Company Quality Manual and Document Control Procedures
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Market Entry Issue Log
| Field | Description / Example |
|---|---|
| Issue ID | MEI-2026-001 |
| Date Identified | 05/04/2026 |
| Product Name | Example Drug Tablet 50mg |
| Dosage Form | Tablet |
| Description of Issue | Delay in submission of registration dossier due to missing stability data. |
| Source of Issue | Regulatory Affairs |
| Reported By | Regulatory Coordinator |
| Initial Impact Assessment | High – Potential market launch delay |
| Immediate Actions Taken | Notified quality department to expedite data generation. |
Annexure-2: Market Entry Issue Tracking Sheet
| Issue ID | Action Item | Responsible Person | Start Date | Due Date | Status | Comments |
|---|---|---|---|---|---|---|
| MEI-2026-001 | Obtain stability data report | QA Analyst | 06/04/2026 | 10/04/2026 | In Progress | Sample analysis underway |
| MEI-2026-001 | Prepare and submit updated dossier | Regulatory Affairs Specialist | 11/04/2026 | 15/04/2026 | Pending | Dependent on data availability |
Annexure-3: Corrective and Preventive Action Plan Template
| Field | Details / Example |
|---|---|
| Issue ID | MEI-2026-001 |
| Root Cause | Delay in coordination between regulatory and stability testing teams. |
| Corrective Actions | Implement cross-departmental communication checklist and weekly status calls. |
| Preventive Actions | Incorporate stability data submission timeline in project milestone tracking. |
| Responsible Person(s) | Regulatory Affairs Manager; QA Team Lead |
| Target Completion Date | 30/04/2026 |
| Verification Method | Review meeting minutes and monitor adherence to new communication protocol for next two market entries. |
| Verification Date | 15/05/2026 |
| Verification Result | Effective with improved timely data submissions observed. |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 10/04/2026 | 1.0 | Initial issue | New SOP creation |